Scrip's five biggest clinical setbacks of 2014, so far�
This article was originally published in Scrip
The close of 2014 is fast approaching, and as the door closes on tax inversion deals, Scrip has taken a look at another area of disappointment for companies so far this year: major clinical trial failures.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.